Clinical and Translational Oncology

, Volume 8, Issue 7, pp 475–481

Inhibitors of angiogenesis

Educational Series Green Series

Abstract

Angiogenesis and neovascularization are important mechanisms for tumor growth, progression and, subsequent metastasis. Cancer cells, as part of an inflammatory process, produce and induce multiple molecules (proangiogenic and antiangiogenic) from the surrounding stromal cells. Vascular Endothelial Growth Factor (VEGF) is the most relevant proangiogenic molecule among them. Many inhibitors of angiogenesis have been developed in the last years with the aim to block the tumor blood supply as a new anticancer strategy. Bevacizumab, an anti-VEGF, has been already approved for its use in colorectal cancer showing prolonged disease free survival as well as overall survival. It shows also important activity in breast, lung, ovarian and kidney cancer. Many others inhibitors are in advanced clinical development and show promising results as well. Current basic and clinical research in this field is generating great expectations for the future of cancer treatment.

Key words

angiogenesis inhibitors antiangiogenesis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst. 1978;61:639–45.PubMedGoogle Scholar
  3. 3.
    Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitis fluid. Science. 1983;219:983–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the P13-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273: 30336–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature bloos vessels in established human tumors follows vascular endothelial growth factor with-drawl. J Clin Invest. 1999;105:159–65.Google Scholar
  7. 7.
    Jain RK. Normalizing tumor vasculature with antiangio genic therapy: a new paradigm for combination therapy. Nature Med. 2001;7:987–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 2004;10:145–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II. Randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–705.PubMedCrossRefGoogle Scholar
  11. 11.
    Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kabbinavar F, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab with irinotecan, fluorouracil and leucovorin in the treatment of metastatic colorectal cancer. N Engl J Med. 2004;550:2335–42.CrossRefGoogle Scholar
  14. 14.
    Giantonio BJ, Catalana PJ, Meropol NJ, et al. High dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;25:16S, abstract #2.Google Scholar
  15. 15.
    Hochster H, et al. Gastointestinal Cancers Symposium, Hollywood, Florida, 2005.Google Scholar
  16. 16.
    Holash J, David S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11593–8.CrossRefGoogle Scholar
  17. 17.
    Morgan JA, Garrett HJ, Schutte H, et al. Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a «treatment-use» trial. Proceedings ASCO. 2006;24:529s, abstract #9540.Google Scholar
  18. 18.
    Rini BI, George DJ, Michaelson JE, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proceedings ASCO. 2006;24:222s, abstract #4522.Google Scholar
  19. 19.
    Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced RCC. European Cancer Conference, ECCO-15. 2005; Personal communication.Google Scholar
  20. 20.
    Gore ME, Scudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology. 2006;20 (6 Suppl 5):S19–24.PubMedGoogle Scholar
  21. 21.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71.PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2006

Authors and Affiliations

  1. 1.Division of Medical Oncology, ICMHO, IDIBAPS, Hospital ClinicUniversity of BarcelonaBarcelonaSpain
  2. 2.Servicio de Oncología MédicaICMHO Hospital ClínicBarcelonaSpain

Personalised recommendations